CSL Limited

Research CSL Limited (CSL.AX) on Bullrun: market cap AUD 92.23B, dividend yield 2.1%. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is AUD 92.23B; dividend yield is 2.1%.

Peer valuation comparison

Latest dividend yield is 2.11% versus a Healthcare sector median of 2.41% (12.4% below).

Five-year financial history

YearRevenueNet incomeFree cash flowGross marginDiluted EPSCashTotal debtEquity
FY2026USD 15.70B-USD 2.58BUSD 2.23B50.8%-5.35USD 1.51BUSD 10.90BUSD 14.80B
FY2025USD 15.43BUSD 3.00BUSD 2.54B51.5%6.17USD 2.16BUSD 11.50BUSD 19.34B
FY2024USD 14.69BUSD 2.64BUSD 1.51B51.5%5.45USD 1.66BUSD 12.18BUSD 17.36B
FY2023USD 13.17BUSD 2.19BUSD 909.00M50.9%4.53USD 1.55BUSD 12.23BUSD 15.79B

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-10-17AUD 92.23Bn/a2.2%4.05

Dividend history

Latest trailing dividend snapshot: annual dividend/share 4.05 AUD, yield 2.1%.

YearDividends/share
FY20264.05 USD
FY20254.52 USD
FY20243.97 USD
FY20233.63 USD

About CSL Limited

CSL Limited engages in the research, development, manufacture, market, and distribution of biopharmaceutical products and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment manufactures, markets, and distributes plasma products, gene therapies, and recombinants.

ETFs that hold CSL Limited

CSL Limited is one of the ten largest holdings of 24 ETFs that investors in Europe can buy. The 8 most traded of them:

ETFWeightTER
iSh Cor MSCI Pacif exJP USD A2.76%0.20%
iShares MSCI Australia UCITS ETF USD (Acc)4.40%0.50%
L&G Asia Pacific ex Japan Equity UCITS ETF2.50%0.10%
Amundi MSCI Pacific Ex Japan SRI Climate Paris Aligned - UCITS ETF DR - EUR (C)5.52%0.45%
HSBC MSCI Pacific ex Japan UCITS ETF2.74%0.15%
iShares MSCI Pacific ex-Japan UCITS ETF USD (Dist)2.77%0.60%
L&G Asia Pacific ex Japan ESG Paris Aligned UCITS ETF4.51%0.16%
Amundi MSCI Pacific Ex Japan SRI Climate Paris Aligned - UCITS ETF DR - EUR (D)5.52%0.45%

Related stock research

Australia stocks Australia Healthcare stocks A-Z stock index

Other Healthcare stocks

Adalta Ltd (1AD) Algorae Pharmaceuticals Ltd (1AI) Acrux Limited (ACR.AX) Actinogen Medical Ltd (ACW) Argenica Therapeutics Ltd (AGN) Arovella Therapeutics Limited (ALA.AX) Anatara Lifesciences Ltd (ANR) Alterity Therapeutics Ltd (ATHE) Amplia Therapeutics Limited (ATX.AX) Avecho Biotechnology Limited (AVE.AX) Bio-Gene Technology Limited (BGT.AX) Biotron Limited (BIT.AX)

Frequently asked questions

What is CSL Limited's market cap?

CSL Limited's market capitalization is AUD 92.23B.

Does CSL Limited pay a dividend?

CSL Limited has a dividend yield of 2.1%.

What does CSL Limited do?

CSL Limited engages in the research, development, manufacture, market, and distribution of biopharmaceutical products and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment manufactures, markets, and distributes plasma products, gene therapies, and recombinants. The CSL Seqirus segment manufactures, markets, and distributes influenza related products and pandemic services to governments.